Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$79.33 USD
+0.02 (0.03%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $79.32 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Edwards Lifesciences Corporation has a PEG ratio of 3.71 compared to the Medical - Instruments industry's PEG ratio of 2.25.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
EW 79.33 +0.02(0.03%)
Will EW be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for EW based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EW
ENSG's Q2 Earnings Beat on Higher Occupancy Rates, Stock Up 9%
HCA Beats Q2 Earnings on Higher Admissions, Ups '25 EPS View
EW: What are Zacks experts saying now?
Zacks Private Portfolio Services
EW Stock Climbs on Q2 Earnings & Revenue Beat, Margins Down
Compared to Estimates, Edwards Lifesciences (EW) Q2 Earnings: A Look at Key Metrics
Robust TMTT Growth to Drive Edwards Lifesciences' Q2 Earnings
Other News for EW
Citadel Advisors LLC Increases Stake in NioCorp Developments Ltd
Agree To Purchase Edwards Lifesciences At $65, Earn 5.2% Using Options
Edwards Lifesciences Corp (EW)'s Winning Formula: Financial Metrics and Competitive Strengths
Sarepta upgraded, Tapestry downgraded: Wall Street's top analyst calls
Daiwa gets more bullish on Edwards Lifesciences, upgrades shares